2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Pemphigus: new trials by email Literature Review of Pemphigus trials Research Report on Pemphigus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. AB-101, Rituximab, Cyclophosphamide - Rheumatoid Arthritis, Pemphigus Vulgaris | Phase 1 | Recruiting | IRIS Research and Development, LLC | 30 | 2024-05-15 | 2024-09-03 |
| A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) DSG3-CAART, CABA-201 - Pemphigus Vulgaris | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 40 | 2020-09-29 | 2026-10-15 |
Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Granulomatosis with Polyangiitis (1) · Immune System Diseases (1) · Lupus Erythematosus, Systemic (1) · Skin Diseases, Vesiculobullous (1)
Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arthritis (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Joint Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Musculoskeletal Diseases (1) · Respiratory Tract Diseases (1) · Rheumatic Diseases (1) · Skin Diseases, Vascular (1)
Cyclophosphamide (1) · Rituximab (1) · fludarabine (1)
Cabaletta Bio (1) · IRIS Research and Development, LLC (1)
United States (2)
Cabaletta Bio (1) · Guillermo J. Valenzuela, M.D. (1) · Kathy I. Perez, M.D. (1)